A recent chikungunya outbreak affected 1.5 million cases in more than 60 countries. The virus causes low mortality but moderate to severe morbidities such as high fever, myalgia, and polyarthritis. The chikungunya virus is transmitted by Aedes spp. mosquitoes, of which the population has increased due to urbanization and global warming. Currently, no commercial vaccine is available, but several candidates are being tested in clinical trials. This review aimed to summarize the recent updates of candidates on each platform, ranging from traditional inactivation, live attenuation with reverse genetics, virus-like particles, viral vectors, and mRNA, mainly focusing on the candidates in clinical trials or recently developed.

中文翻译：

---

基孔肯雅疫苗：2023 年更新。

最近爆​​发的基孔肯雅热疫情影响了 60 多个国家的 150 万病例。该病毒导致低死亡率，但会导致中度至重度并发症，例如高烧、肌痛和多发性关节炎。基孔肯雅病毒由伊蚊属传播。蚊子，由于城市化和全球变暖，蚊子的数量有所增加。目前，尚无商业疫苗可用，但有几种候选疫苗正在临床试验中进行测试。本综述旨在总结各平台候选药物的近期更新，从传统灭活、反向遗传活体减毒、病毒样颗粒、病毒载体、mRNA，主要关注临床试验中或最近开发的候选药物。